ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management
New $135 Million Credit Facility Replaces Existing $159 Million Credit Facility, a 15% Decrease in Total Debt
Further Supports Rapid Q-o-Q and Y-o-Y Earnings Accretion
Related news for (ADMA)
- ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
- ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
- ADMA Biologics Statement on Tariffs
- ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
- ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update